ATAI
Earnings in 6 days · May 13, 2026 · Before open
Signal
Bullish Setup2
Price
1
Move+4.25%Strong session
Volume
1
Volume0.8× avgNormal activity
Technical
1
RSIRSI 50Momentum positive
PRICE
Prev Close
4.00
Open
4.01
Day Range3.99 – 4.24
3.99
4.24
52W Range1.29 – 6.75
1.29
6.75
53% of range
VOLUME & SIZE
Avg Volume
4.9M
FUNDAMENTALS
P/E Ratio
-1.4x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.44
Market-like
Quick Read
TrendInsufficient MA data
Momentum
NEUTRAL
rev +1228% · -165% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 11.7 · FCF negative
Lean Bullish
Key MetricsTTM
Market Cap$786.57M
Revenue TTM$4.09M
Net Income TTM-$660.05M
Free Cash Flow-$114.21M
Gross Margin-165.1%
Net Margin-16142.0%
Operating Margin-2862.8%
Return on Equity-389.7%
Return on Assets-212.5%
Debt / Equity0.01
Current Ratio11.74
EPS TTM$-2.10

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
49/100
Liquidity
11.74Strong
Leverage
0.01Strong
Coverage
-100.6xConcern
ROE
-389.7%Concern
ROIC
-40.7%Concern
Cash
$85MStrong
ANALYST COVERAGE4 analysts
BUY
+175.8%upside to target
L $10.00
Med $11.50consensus
H $15.00
Buy
4100%
4 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
RSI RangeRSI 50 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 11.74 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · Before OpenMay 8, 2026
Tomorrow
DEx-Dividend DateAug 5, 2026
In 90 days
PDividend PaymentAug 20, 2026
In 105 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

RallyDeath Cross · 50D trails 200D by 8.8%

+7.5% vs SMA 50 · -2.0% vs SMA 200

Momentum

RSI50.2
Neutral territory
MACD+0.17
Above zero — bullish momentum · compressing
Market Position
Price Levels
52W High
$6.75+61.9%
Current
$4.17
EMA 50
$4.00-4.0%
EMA 200
$3.89-6.7%
52W Low
$1.29-69.1%
52-Week RangeMid-range
$1.2953th %ile$6.75
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 9 analysts
Analyst revisions:EPS↓ Revised DownRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$3.0M
$2.4M$3.6M
-$0.62
±5%
High9
FY2026(current)
$507692
$507692$507692
-83.1%-$0.48
±41%
High9
FY2027
$240000
$240000$240000
-52.7%-$0.49
±34%
High8
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryATAI
Last 8Q
-30.7%avg beat
Beat 3 of 8 quartersMissed 5 Estimates rising
+15%
Q2'24
-112%
Q3'24
-7%
Q4'24
-71%
Q1'25
+21%
Q2'25
-17%
Q3'25
-133%
Q4'25
+58%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
1 Buy/5 SellsNet Selling
Apeiron Investment …10 Percent Own…
$19.0M
Aug 14
BUY
Kirpekar SahilChief Business…
$66K
Mar 21
SELL
Craig Kevin JamesChief Medical …
$16K
Mar 21
SELL
Rao SrinivasSee Remarks
$102K
Mar 21
SELL
Johnson Anne Nageng…CFO
$45K
Mar 21
SELL
Short Glenn FrankChief Scientif…
$18K
Mar 21
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
UBS Group AG
7.4M
2
Candriam S.C.A.
3.1M
3
Brown University
719K
4
CenterBook Partners LP
707K
5
AdvisorShares Investments LLC
568K
6
Sumitomo Mitsui Trust Holdings, Inc.
568K
7
STABLEFORD CAPITAL II LLC
286K
8
Nuveen, LLC
177K
News & Activity

ATAI News

20 articles · 4h ago

About

who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Country
Germany
Kavita PankeSenior Vice President of New Product, Planning & Commercial
Jason AweVice President of Investor Relations